课题基金 / 基金详情

CORE--ADVANCED TECHNOLOGY LABORATORIES

CORE--ADVANCED TECHNOLOGY LABORATORIES
核心--先进技术实验室
批准号:
5205118
负责人:
CHARLES VAN DER HORST
金额:
$0.0万
依托单位:
--
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

CHARLES VAN DER HORST的其他基金

相似基金

相关文献

中文摘要
翻译
到目前为止一直用作次要终点的病毒学标记 ACTG的大多数议定书已被证明是不充分的。更新的 更定量、更快、更便宜的技术有 这是必要的。最重要的是,这些新的标志物应该随着疾病的变化而变化。 进展或有效的药物治疗。更快速的检测 随着药物敏感性的增加,也需要立即进行药敏测定 许多患者长时间接受药物治疗。全 这些化验中的一项应该与从 有耐心的。 这个实验室以前的工作表明,几乎所有的 在无细胞血浆中发现的传染性艾滋病毒以免疫的形式存在 复合体。感染性免疫复合体很容易和有效地 用聚乙二醇从血浆中沉淀出来。采取的程序 将开发这些功能的优势,将:(1)改进 P24抗原检测,使其更具临床相关性和(2)流线型 直接筛查血浆中敏感或敏感的药物敏感性试验 耐药菌株。这项化验将帮助临床医生确定最佳的 在更适当的时间内为特定患者使用的药物 (1至2周)。 除了开发新的病毒学标记外,实验室还将 继续通过以下方式为ACTG提供所需的病毒学支持 进行HIV细胞和血浆的定量培养和p24抗原 化验。实验室还将继续参与开发一种 从细胞中分离耐药菌株的共识方案 以及它们的临床相关性的确定。 该实验室的长期目标是调查 HIV自然历史和发病机制中的感染性免疫复合体 感染。
英文摘要
The virologic markers that to date have been used as secondary endpoints in most of The ACTG protocols have been shown to be inadequate. Newer techniques that are more quantitative, faster, and less expensive are necessary. Most importantly, these new markers should change with disease progression or with effective drug therapy. More rapid assays for the determination of drug sensitivity are also needed immediately as increasing numbers of patients stay on medication for prolonged periods of time. All of these assays should correlate with the clinical data obtained from the patient. Previous work in this laboratory has indicated that virtually all of the infectious HIV found in cell-free plasma is in the form of immune complexes. Infectious immune complexes are easily and efficiently precipitated from plasma with polyethylene glycol. Procedures taking advantage of these features will be developed that will: (1) improve the p24 antigen assay and make it more clinically relevant and (2) streamline drug sensitivity testing by directly screening plasma for sensitive or resistant isolates. This assay will help the clinician determine the best drug to use for a particular patient in a more appropriate amount of time (1 to 2 weeks). In addition to the development of new virologic markers the laboratory will continue to provide the required virologic support of the ACTG by performing quantitative HIV cell and plasma cultures and p24 antigen assays. The lab will also continue to participate in the development of a consensus protocol for the isolation of drug resistant isolates from cells and the determination of their clinical relevance. The long term goal of the laboratory is to investigate the role of infectious immune complexes in the natural history and pathogenesis of HIV infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COMPLICATIONS OF HIV DISEASE AGENDA
  • 批准号:
    5205111
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    CHARLES VAN DER HORST
  • 依托单位:
    --
NEUROLOGY AGENDA
  • 批准号:
    5205112
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    CHARLES VAN DER HORST
  • 依托单位:
    --
PHARMACOLOGY AGENDA
  • 批准号:
    5205114
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    CHARLES VAN DER HORST
  • 依托单位:
    --
ADULT AIDS CLINICAL RESEARCH
海外基金